MFDS restricts prescription of Hanmi Pharm’s 27th new Korean drug, ‘Olita Tab’

The 27^th new Korean drug developed by Hanmi Pharm, ‘Olita Tab’ was restricted to prescribe for new patients as encountering to an adverse response which was not reflected in its clinical trials.

On the 30^th, the Ministry of Food and Drug Safety(MFDS) announced distribution of a safety letter to medical personnel and consumers’ associations in Korea, in order to inform Olita Tab(olmutinib hydr...